Applied DNA Sciences, Inc. (APDN)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Applied DNA Sciences, Inc. (APDN) with AI Score 46/100 (Weak). Applied DNA Sciences, Inc. specializes in DNA-based solutions for diagnostics, drug development, supply chain security, and anti-counterfeiting. Sector: Healthcare.
Last analyzed: Mar 15, 2026Applied DNA Sciences, Inc. (APDN) Healthcare & Pipeline Overview
Applied DNA Sciences, Inc. leverages DNA technology for diagnostics, supply chain security, and anti-counterfeiting. Its key products include molecular tags, DNA readers, and COVID-19 diagnostic tests. The company operates in the medical diagnostics and supply chain security sectors, facing competition from established players and evolving regulatory landscapes.
What Is the Investment Thesis for APDN?
Applied DNA Sciences, Inc. presents a speculative investment opportunity within the medical diagnostics and supply chain security sectors. The company's diverse product offerings, including DNA-based diagnostics and anti-counterfeiting solutions, cater to growing markets. Key value drivers include the expansion of its COVID-19 testing services and the adoption of its supply chain security technologies. The company's gross margin stands at 23.1%. However, the company's negative P/E ratio of -0.22 and a significant negative profit margin of -1515.9% indicate financial challenges. Growth catalysts include potential partnerships and regulatory approvals. Potential risks include competition and the need for additional funding.
Based on FMP financials and quantitative analysis
APDN Key Highlights
- Market capitalization of $0.01 billion, reflecting its small-cap status.
- Negative P/E ratio of -0.22, indicating the company is not currently profitable.
- Profit margin of -1515.9%, highlighting significant losses.
- Gross margin of 23.1%, demonstrating some profitability at the product level.
- Beta of 0.13, suggesting low volatility compared to the overall market.
Who Are APDN's Competitors?
What Are APDN's Key Strengths?
- Proprietary DNA-based technology platform.
- Diverse product portfolio addressing multiple markets.
- Expertise in supply chain security and diagnostics.
- Established partnerships with key customers.
What Are APDN's Weaknesses?
- Negative profitability and high operating losses.
- Small market capitalization and limited financial resources.
- Dependence on key customers and contracts.
- Limited brand recognition compared to larger competitors.
What Could Drive APDN Stock Higher?
- Potential FDA approvals for new diagnostic tests.
- Expansion of COVID-19 testing contracts.
- Adoption of supply chain security solutions by new customers.
- Results from clinical trials for invasive circulating tumor cell technology.
What Are the Key Risks for APDN?
- Competition from larger and more established companies.
- Regulatory hurdles and changing industry standards.
- Economic downturns and reduced healthcare spending.
- Technological obsolescence and the emergence of alternative solutions.
- Dependence on key customers and contracts.
What Are the Growth Opportunities for APDN?
- Growth opportunity 1: Expansion of COVID-19 Testing Services: Applied DNA Sciences can capitalize on the ongoing need for COVID-19 testing by expanding its LineaTM COVID-19 Assay Kit and safeCircle offerings. The global COVID-19 diagnostics market is expected to remain substantial, driven by new variants and the need for continuous monitoring. Success hinges on securing contracts with schools, workplaces, and communities, and adapting to evolving testing protocols. Timeline: Ongoing.
- Growth opportunity 2: Adoption of Supply Chain Security Solutions: The company's SigNature molecular tags and CertainT platform offer a unique value proposition for brands seeking to combat counterfeiting and ensure product authenticity. The global anti-counterfeiting packaging market is projected to reach billions of dollars. Key to success is demonstrating the effectiveness and cost-efficiency of its solutions to potential clients in various industries. Timeline: Ongoing.
- Growth opportunity 3: Development of Invasive Circulating Tumor Cell Technology: Applied DNA Sciences' research into capturing and identifying invasive circulating tumor cells presents a significant opportunity in the oncology diagnostics market. The market for liquid biopsy technologies is rapidly expanding. Success depends on clinical trial outcomes, regulatory approvals, and commercialization partnerships. Timeline: Future (dependent on research progress).
- Growth opportunity 4: Partnerships and Collaborations: Strategic alliances with pharmaceutical companies, diagnostic providers, and supply chain stakeholders can accelerate the adoption of Applied DNA Sciences' technologies. Collaborations can provide access to new markets, funding, and expertise. Identifying and securing mutually beneficial partnerships is crucial for growth. Timeline: Ongoing.
- Growth opportunity 5: Geographic Expansion: Applied DNA Sciences currently operates in the United States, Europe, and Asia. Expanding its geographic footprint to new markets can drive revenue growth. This requires adapting its products and services to local regulations and market needs. Identifying and prioritizing high-growth regions is essential. Timeline: Ongoing.
What Opportunities Does APDN Have?
- Expansion of COVID-19 testing services.
- Adoption of supply chain security solutions.
- Development of invasive circulating tumor cell technology.
- Strategic partnerships and collaborations.
What Threats Does APDN Face?
- Competition from larger and more established companies.
- Regulatory hurdles and changing industry standards.
- Economic downturns and reduced healthcare spending.
- Technological obsolescence and the emergence of alternative solutions.
What Are APDN's Competitive Advantages?
- Proprietary DNA-based technology.
- Patented solutions for supply chain security and diagnostics.
- Established relationships with key customers.
- Expertise in DNA-based research and development.
What Does APDN Do?
Founded in 1983 and headquartered in Stony Brook, New York, Applied DNA Sciences, Inc. has evolved from its origins as Datalink Systems, Inc. to become a developer and marketer of DNA-based technology solutions. The company operates in the nucleic acid-based in vitro diagnostics and preclinical nucleic-acid based drug development and manufacturing markets, as well as providing supply chain security, anti-counterfeiting, and anti-theft technology. Applied DNA Sciences' product portfolio includes SigNature molecular tags, which are used to protect against counterfeiting and strengthen supply chain security. SigNify IF portable DNA readers and SigNify consumable reagent test kits provide real-time authentication of molecular tags in the field. The CertainT platform offers tagging, testing, and tracking solutions. The company also manufactures and sells the LineaTM COVID-19 Assay Kit, a PCR-based molecular diagnostic test kit, and the safeCircle COVID-19 diagnostic test kit. Applied DNA Sciences also provides preclinical contract research and manufacturing services for the nucleic acid-based therapeutic markets, as well as contract research services to RNA based drug and biologic customers for preclinical studies. Additionally, the company is developing an invasive circulating tumor cell capture and identification technology. The company operates in the United States, Europe, Asia, and internationally.
What Products and Services Does APDN Offer?
- Develops and markets DNA-based technology solutions.
- Offers solutions for nucleic acid-based in vitro diagnostics.
- Provides preclinical nucleic-acid based drug development and manufacturing services.
- Offers supply chain security, anti-counterfeiting, and anti-theft technology.
- Manufactures and sells COVID-19 PCR-based molecular diagnostic test kits.
- Provides contract research services to RNA based drug and biologic customers.
- Develops technology for capturing and identifying invasive circulating tumor cells.
How Does APDN Make Money?
- Sells DNA-based technology solutions to various industries.
- Generates revenue from the sale of diagnostic test kits.
- Provides contract research and manufacturing services.
- Licenses its technology to partners.
What Industry Does APDN Operate In?
Applied DNA Sciences, Inc. operates in the competitive medical diagnostics and supply chain security industries. The medical diagnostics market is driven by technological advancements and increasing demand for rapid and accurate testing. The supply chain security market is growing due to rising concerns about counterfeiting and product integrity. Applied DNA Sciences competes with companies offering similar DNA-based solutions and traditional security measures. The company's success depends on its ability to innovate, secure partnerships, and navigate regulatory hurdles. Competitors include companies like AFMD, ARAV, AWH, BPTS, and DMTKQ.
Who Are APDN's Key Customers?
- Pharmaceutical companies
- Diagnostic providers
- Supply chain stakeholders
- Brands seeking anti-counterfeiting solutions
APDN Financials
APDN Latest News
No recent news available for APDN.
APDN Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for APDN.
Price Targets
Wall Street price target analysis for APDN.
APDN MoonshotScore
What does this score mean?
The MoonshotScore rates APDN's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Who Are APDN's Competitors?
Leadership: James A. Hayward Sc.D.
CEO
James A. Hayward Sc.D. has served as the CEO of Applied DNA Sciences, Inc. He has extensive experience in biotechnology and molecular biology. His academic credentials include a Sc.D., reflecting his deep scientific expertise. Prior to joining Applied DNA Sciences, he held various leadership positions in the biotechnology industry, focusing on research and development. He is responsible for guiding the company's strategic direction and overseeing its operations.
Track Record: Under Dr. Hayward's leadership, Applied DNA Sciences, Inc. has expanded its product portfolio and entered new markets. He has overseen the development and commercialization of the LineaTM COVID-19 Assay Kit and the expansion of the company's supply chain security solutions. He has also focused on building strategic partnerships and collaborations to drive growth.
What Investors Ask About Applied DNA Sciences, Inc. (APDN) — Healthcare
What does Applied DNA Sciences, Inc. do?
Applied DNA Sciences, Inc. develops and commercializes DNA-based technology solutions for various industries, including diagnostics, drug development, and supply chain security. The company's core offerings include molecular tags for anti-counterfeiting, DNA readers for authentication, and COVID-19 diagnostic test kits. It also provides contract research and manufacturing services for nucleic acid-based therapeutics. The company aims to leverage its DNA technology platform to address critical challenges in healthcare and supply chain integrity, operating in the United States, Europe, and Asia.
What do analysts say about APDN stock?
AI analysis is pending for Applied DNA Sciences, Inc. Therefore, a comprehensive analyst consensus is not currently available. Investors should conduct their own due diligence and consult with financial advisors before making any investment decisions. Key valuation metrics to consider include the company's market capitalization, P/E ratio, profit margin, and growth prospects. Factors influencing the stock's performance include regulatory approvals, contract wins, and technological advancements.
What are the main risks for APDN?
Applied DNA Sciences, Inc. faces several risks, including intense competition from larger companies in the diagnostics and supply chain security markets. Regulatory hurdles and changing industry standards could impact the company's ability to commercialize its products. Economic downturns and reduced healthcare spending could also negatively affect revenue. Additionally, the company faces the risk of technological obsolescence and the emergence of alternative solutions. Dependence on key customers and contracts poses a concentration risk.
What are the key factors to evaluate for APDN?
Applied DNA Sciences, Inc. (APDN) currently holds an AI score of 46/100, indicating low score. Key strength: Proprietary DNA-based technology platform. Primary risk to monitor: Competition from larger and more established companies. This is not financial advice.
How frequently does APDN data refresh on this page?
APDN prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven APDN's recent stock price performance?
Recent price movement in Applied DNA Sciences, Inc. (APDN) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary DNA-based technology platform. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider APDN overvalued or undervalued right now?
Determining whether Applied DNA Sciences, Inc. (APDN) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying APDN?
Before investing in Applied DNA Sciences, Inc. (APDN), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is based on the most recent available information.
- AI analysis is pending for APDN.